Proliferative State of Normal In Vitro Colony-forming Cells During Development of L5222 Rat Leukemia and Their Reaction to Chemotherapy
In the experimental rat leukemia, L5222, the decrease of normal in vitro colony-forming cells (CFU-C) after chemotherapy with daunomycin is much less than in non-leukemic controls. The leukemia is therefore used here to test the hypothesis that in leukemia the CFU-C are expelled from the active cell...
Gespeichert in:
Veröffentlicht in: | Blood 1978-02, Vol.51 (2), p.221-227 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 227 |
---|---|
container_issue | 2 |
container_start_page | 221 |
container_title | Blood |
container_volume | 51 |
creator | Harriss, E.B. Hoelzer, D. |
description | In the experimental rat leukemia, L5222, the decrease of normal in vitro colony-forming cells (CFU-C) after chemotherapy with daunomycin is much less than in non-leukemic controls. The leukemia is therefore used here to test the hypothesis that in leukemia the CFU-C are expelled from the active cell cycle to a resting state and are thereby less sensitive to cycle-dependent chemotherapeutic agents. The L5222 leukemia has the advantage that the leukemic blast cells do not form colonies in agar culture so that normal CFU-C can be assessed under leukemic conditions. To compare the proportions of CFU-C in the S-phase in normal and leukemic rats, two S-phase–specific agents, 3H-thymidine and hydroxyurea, were used to kill proliferating bone marrow cells. Following treatment with 3H-thymidine in vitro, about 41% of the CFU-C were killed in normal and about 25% in leukemic bone marrow. Hydroxyurea administered in vivo resulted in the death of about 33% and 26%, respectively. The results indicate that fewer normal CFU-C are in S-phase in the L5222 leukemia, which might help to explain how enough normal stem cells survive chemotherapy to regenerate the bone marrow. |
doi_str_mv | 10.1182/blood.V51.2.221.221 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_83823085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497120727230</els_id><sourcerecordid>83823085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3131-8ba74cad43d63492d6f7b5617dd8bce0433facb3244941ec6af851529e0f71b93</originalsourceid><addsrcrecordid>eNp9kMtu1DAUhi3EbWh5Alh4xS5T35I4CxZoyqXSCFAp3VqOfcwYknhqOyPNE_DadZiqSxZHR-fy_0fnQ-gNJWtKJbvohxDs-rama7ZmjC7xBK1ozWRFCCNP0YoQ0lSia-lL9Cql34RQwVn9Aj1vGCGSr9Df7zEM3kHU2R8A_8g6Aw4Ofw1x1AO-mvCtzzHgTRjCdKxcafvpF97AMCR8OceluIQDDGE_wpQX6bZmjOFrnfEW5j8weo31ZPHNDnzE16BN9mHCuXjuYAx5V27vj-fomdNDgtcP-Qz9_PTxZvOl2n77fLX5sK0Mp5xWstetMNoKbhsuOmYb1_Z1Q1trZW-ACM6dNj1nQnSCgmm0k3UB0gFxLe07fobenXz3MdzNkLIafTLlGz1BmJOSXDJOZF0W-WnRxJBSBKf20Y86HhUlaqGv_tFXhb5iqpBfoqjePtjP_Qj2UXPCXcbvT2MoLx48RJWMh8mA9RFMVjb4_9rfA099lwA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>83823085</pqid></control><display><type>article</type><title>Proliferative State of Normal In Vitro Colony-forming Cells During Development of L5222 Rat Leukemia and Their Reaction to Chemotherapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Harriss, E.B. ; Hoelzer, D.</creator><creatorcontrib>Harriss, E.B. ; Hoelzer, D.</creatorcontrib><description>In the experimental rat leukemia, L5222, the decrease of normal in vitro colony-forming cells (CFU-C) after chemotherapy with daunomycin is much less than in non-leukemic controls. The leukemia is therefore used here to test the hypothesis that in leukemia the CFU-C are expelled from the active cell cycle to a resting state and are thereby less sensitive to cycle-dependent chemotherapeutic agents. The L5222 leukemia has the advantage that the leukemic blast cells do not form colonies in agar culture so that normal CFU-C can be assessed under leukemic conditions. To compare the proportions of CFU-C in the S-phase in normal and leukemic rats, two S-phase–specific agents, 3H-thymidine and hydroxyurea, were used to kill proliferating bone marrow cells. Following treatment with 3H-thymidine in vitro, about 41% of the CFU-C were killed in normal and about 25% in leukemic bone marrow. Hydroxyurea administered in vivo resulted in the death of about 33% and 26%, respectively. The results indicate that fewer normal CFU-C are in S-phase in the L5222 leukemia, which might help to explain how enough normal stem cells survive chemotherapy to regenerate the bone marrow.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood.V51.2.221.221</identifier><identifier>PMID: 620083</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; Bone Marrow Cells ; Cell Division ; Cell Survival - drug effects ; Cells, Cultured ; Daunorubicin - therapeutic use ; Female ; Hydroxyurea - pharmacology ; Leukemia, Experimental - drug therapy ; Rats ; Thymidine - pharmacology ; Time Factors</subject><ispartof>Blood, 1978-02, Vol.51 (2), p.221-227</ispartof><rights>1978 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3131-8ba74cad43d63492d6f7b5617dd8bce0433facb3244941ec6af851529e0f71b93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/620083$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harriss, E.B.</creatorcontrib><creatorcontrib>Hoelzer, D.</creatorcontrib><title>Proliferative State of Normal In Vitro Colony-forming Cells During Development of L5222 Rat Leukemia and Their Reaction to Chemotherapy</title><title>Blood</title><addtitle>Blood</addtitle><description>In the experimental rat leukemia, L5222, the decrease of normal in vitro colony-forming cells (CFU-C) after chemotherapy with daunomycin is much less than in non-leukemic controls. The leukemia is therefore used here to test the hypothesis that in leukemia the CFU-C are expelled from the active cell cycle to a resting state and are thereby less sensitive to cycle-dependent chemotherapeutic agents. The L5222 leukemia has the advantage that the leukemic blast cells do not form colonies in agar culture so that normal CFU-C can be assessed under leukemic conditions. To compare the proportions of CFU-C in the S-phase in normal and leukemic rats, two S-phase–specific agents, 3H-thymidine and hydroxyurea, were used to kill proliferating bone marrow cells. Following treatment with 3H-thymidine in vitro, about 41% of the CFU-C were killed in normal and about 25% in leukemic bone marrow. Hydroxyurea administered in vivo resulted in the death of about 33% and 26%, respectively. The results indicate that fewer normal CFU-C are in S-phase in the L5222 leukemia, which might help to explain how enough normal stem cells survive chemotherapy to regenerate the bone marrow.</description><subject>Animals</subject><subject>Bone Marrow Cells</subject><subject>Cell Division</subject><subject>Cell Survival - drug effects</subject><subject>Cells, Cultured</subject><subject>Daunorubicin - therapeutic use</subject><subject>Female</subject><subject>Hydroxyurea - pharmacology</subject><subject>Leukemia, Experimental - drug therapy</subject><subject>Rats</subject><subject>Thymidine - pharmacology</subject><subject>Time Factors</subject><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1978</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtu1DAUhi3EbWh5Alh4xS5T35I4CxZoyqXSCFAp3VqOfcwYknhqOyPNE_DadZiqSxZHR-fy_0fnQ-gNJWtKJbvohxDs-rama7ZmjC7xBK1ozWRFCCNP0YoQ0lSia-lL9Cql34RQwVn9Aj1vGCGSr9Df7zEM3kHU2R8A_8g6Aw4Ofw1x1AO-mvCtzzHgTRjCdKxcafvpF97AMCR8OceluIQDDGE_wpQX6bZmjOFrnfEW5j8weo31ZPHNDnzE16BN9mHCuXjuYAx5V27vj-fomdNDgtcP-Qz9_PTxZvOl2n77fLX5sK0Mp5xWstetMNoKbhsuOmYb1_Z1Q1trZW-ACM6dNj1nQnSCgmm0k3UB0gFxLe07fobenXz3MdzNkLIafTLlGz1BmJOSXDJOZF0W-WnRxJBSBKf20Y86HhUlaqGv_tFXhb5iqpBfoqjePtjP_Qj2UXPCXcbvT2MoLx48RJWMh8mA9RFMVjb4_9rfA099lwA</recordid><startdate>197802</startdate><enddate>197802</enddate><creator>Harriss, E.B.</creator><creator>Hoelzer, D.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>197802</creationdate><title>Proliferative State of Normal In Vitro Colony-forming Cells During Development of L5222 Rat Leukemia and Their Reaction to Chemotherapy</title><author>Harriss, E.B. ; Hoelzer, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3131-8ba74cad43d63492d6f7b5617dd8bce0433facb3244941ec6af851529e0f71b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1978</creationdate><topic>Animals</topic><topic>Bone Marrow Cells</topic><topic>Cell Division</topic><topic>Cell Survival - drug effects</topic><topic>Cells, Cultured</topic><topic>Daunorubicin - therapeutic use</topic><topic>Female</topic><topic>Hydroxyurea - pharmacology</topic><topic>Leukemia, Experimental - drug therapy</topic><topic>Rats</topic><topic>Thymidine - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Harriss, E.B.</creatorcontrib><creatorcontrib>Hoelzer, D.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harriss, E.B.</au><au>Hoelzer, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proliferative State of Normal In Vitro Colony-forming Cells During Development of L5222 Rat Leukemia and Their Reaction to Chemotherapy</atitle><jtitle>Blood</jtitle><addtitle>Blood</addtitle><date>1978-02</date><risdate>1978</risdate><volume>51</volume><issue>2</issue><spage>221</spage><epage>227</epage><pages>221-227</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>In the experimental rat leukemia, L5222, the decrease of normal in vitro colony-forming cells (CFU-C) after chemotherapy with daunomycin is much less than in non-leukemic controls. The leukemia is therefore used here to test the hypothesis that in leukemia the CFU-C are expelled from the active cell cycle to a resting state and are thereby less sensitive to cycle-dependent chemotherapeutic agents. The L5222 leukemia has the advantage that the leukemic blast cells do not form colonies in agar culture so that normal CFU-C can be assessed under leukemic conditions. To compare the proportions of CFU-C in the S-phase in normal and leukemic rats, two S-phase–specific agents, 3H-thymidine and hydroxyurea, were used to kill proliferating bone marrow cells. Following treatment with 3H-thymidine in vitro, about 41% of the CFU-C were killed in normal and about 25% in leukemic bone marrow. Hydroxyurea administered in vivo resulted in the death of about 33% and 26%, respectively. The results indicate that fewer normal CFU-C are in S-phase in the L5222 leukemia, which might help to explain how enough normal stem cells survive chemotherapy to regenerate the bone marrow.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>620083</pmid><doi>10.1182/blood.V51.2.221.221</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0006-4971 |
ispartof | Blood, 1978-02, Vol.51 (2), p.221-227 |
issn | 0006-4971 1528-0020 |
language | eng |
recordid | cdi_proquest_miscellaneous_83823085 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Animals Bone Marrow Cells Cell Division Cell Survival - drug effects Cells, Cultured Daunorubicin - therapeutic use Female Hydroxyurea - pharmacology Leukemia, Experimental - drug therapy Rats Thymidine - pharmacology Time Factors |
title | Proliferative State of Normal In Vitro Colony-forming Cells During Development of L5222 Rat Leukemia and Their Reaction to Chemotherapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T22%3A15%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proliferative%20State%20of%20Normal%20In%20Vitro%20Colony-forming%20Cells%20During%20Development%20of%20L5222%20Rat%20Leukemia%20and%20Their%20Reaction%20to%20Chemotherapy&rft.jtitle=Blood&rft.au=Harriss,%20E.B.&rft.date=1978-02&rft.volume=51&rft.issue=2&rft.spage=221&rft.epage=227&rft.pages=221-227&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood.V51.2.221.221&rft_dat=%3Cproquest_cross%3E83823085%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=83823085&rft_id=info:pmid/620083&rft_els_id=S0006497120727230&rfr_iscdi=true |